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Factors influencing ADME
A. Physico-chemical properties of the element 
(radioactive isotope) 
B. Physico-chemical properties of the 
radiolabeled drug
C. Organ/tissue characteristics
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Common elements used in NM their dominant 
localization and excretion
Element Dominant localization Dominant excretion
Rb Muscule Urine
Cs Muscule Urine
Cu Liver Urine
Ag Protein Feces
Au Liver Urine
Sr Bone Feces
Ba Bone Urine+Feces
Ra Bone Urine+Feces
Ga Bone, muscle Feces
In Bone, liver Feces
Tl Muscle Feces
A
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Element Dominant localization Dominant excretion
Sc Bone, liver Feces
Y Bone Urine
Sm Liver, bone Feces + Urine
Zr Bone Feces
P Muscle, bone Urine
Cr Bone, blood Urine
Mo Liver Urine
F Bone Urine
I Thyroid Urine
Tc GIT Urine
Common elements used in NM their dominant 
localization and excretion
A
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Physico-chemical properties of the 
radiolabeled drug
• Ionization/oxidation state /solubility at 
physiologic pH
• Protein /tissue/cell binding affinity
B
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Organ/tissue characteristics
The rate of delivery and potential amount of drug distributed
into tissues is determined by
➢ Cardiac output
➢ Regional blood flow
➢ Capillary permeability 
➢ Tissue volume
➢ Presence of characteristic receptors for the 
radiopharmaceutical administered
Distribution to well perfused organs is faster (liver, kidney, brain)
Distribution to poorly perfused organs is slower (muscle, most 
visceral organs, skin, and fat)
C
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One-compartment open model - the simplest way to describe 
the process of drug distribution and elimination in the 
body. 
This model assumes:
➢ the drug can enter or leave the body and the body acts like 
a single, uniform compartment. 
➢ the drug is injected all at once into a box, or compartment
➢ the drug distributes instantaneously and homogenously 
throughout the compartment.
The simplest route of drug administration from a modeling 
perspective is a rapid intravenous injection (IV bolus). 
Drug elimination also occurs from the compartment 
immediately after injection.
Compartmental distribution
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Compartmental distribution
1.Concentration
2. Volume
Central 
compartment
1. Concentration
2. Volume
Periferal
compartment
1. Concentration
2. Volume
1. 
2. 
Application of
drug
Application of
drug
Elimination
(urine, feces, ...)
Elimination
(urine, feces, ...)
k2,1k1,2
9
Compartmental distribution
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2. Volume
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Concentration of drug in blood after various types of 
administration
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Volume of distribution
• The space in which this volume is enclosed is the 
compartment
• parameter that characterizes the distribution of a drug 
is the volume of distribution (Vd)
• the ratio of the dose administered, divided by the 
plasma concentration
Vd= D/C0
Not an actual volume :  very lipophilic drugs have Vd values that are 
many times greater than the actual body volume
In RP, Vd depends on the route of administration: lungs volume for
aerosol, cerebrospinal fluid volume for the tracer administered
intrathecally, blood volume for i.v. radiopharmaceuticals.
http://www.icp.org.nz/icp_t3.html
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Physico-chemical properties of the radiolabeled drug
➢ Mw and shape (especially for protein RP)
➢ Protein binding
➢ Lipid solubility/partition coefficient
➢ Presence of specific drug receptors 
➢ Specific transport mechanisms
➢ Stability of the radiolabeled compound
➢ Purity of the radiopharmaceutical preparation 
➢ Pathophysiological state of the patient 
➢ Presence/ absence of interfering drugs
13
Biodistribution of RPs
Protein binding of radiopharmaceuticals
Is greatly influenced by a number of factors, such as:
➢ the charge on the radiopharmaceutical molecule 
➢ pH
➢ the nature of the protein
➢ the concentration of anions in the plasma
❖ Nonspecific binding to albumin and other plasma proteins is correlated 
positively and linearly with increasing lipophilicity.
❖ Proteins contain hydroxyl, carboxyl, and amino groups which determine 
their configuration and the extent and strength of protein binding to the 
radiopharmaceutical. 
❖ Metal complexes can exchange the metal ions with proteins because of 
the stronger affinity of the metal for the protein. This process is called 
“trans-chelation” and leads to in vivo metabolism of the complex. 
e.g.  67Ga-citrate exchanges 67Ga with transferrin to form 67Ga-transferrin in 
the plasma 14
The extent of protein binding of any new radiopharmaceutical 
should be determined before its clinical use.
Protein-binding of radiopharmaceuticals in plasma samples 
can be measured by several techniques including:
Size-exclusion chromatography (SEC)
Trichloroacetic acid (TCA) precipitation 
Dialysis
Ultrafiltration
Protein binding of radiopharmaceuticals
Cu - drug concentration in 
ultrafiltrate(unbound) and 
Ct - total drug concentration before the  
experiment 
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The protein binding of radiopharmaceuticals ranges from 
negligible (< 5 %) for 201Tl-thallous chloride and 99mTc-DTPA 
(most formulations) to as high as 79-90 % for 99mTc-MAG3.
α1-antitrypsin is responsible for binding 
99mTc-exametazime
99mTc-glucoheptonate
99mTc-DTPA
99mTc-iminodiacetic acid agents
Albumin is the main plasma protein involved in binding
99mTc-medronate (99mTc-MDP) and
99mTc-DMSA 
α2-globulin binds 99mTc-MAG3
Protein binding of radiopharmaceuticals
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Mechanisms of Localization of RP
Isotope dillution
Capillary blockade
Cellular migration
Cell sequestration
Simple (passive) diffusion
Facilitated diffusion
Active Transport
Phagocytosis
Cascular permeability and capillary leakage
Cell proliferation
Metabolic trapping
Metabolic substrates
Tissue hypoxia
Specific receptor binding / binding to tumor antigens
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Isotope Dilution
Diluting a radiotracer (or tracer) of known activity (or mass) in 
an unknown volume. 
Measuring the degree to which the radiotracer was diluted by 
the unknown volume, one can determine the total volume 
(or mass) of the unknown volume. 
➢ for quantitative determination of RBC volume (mass), 
plasma volume, and total blood volume the radiotracer 
must remain only in the blood volume to be measured.
e.g. Nondiffusible, radiolabeled, 51Cr-RBCs are used to
measure RBC mass, while 125I-HSA is used to measure
plasma volume.
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Physical trapping of particles in capillaries and pre-capillary arterioles. 
➢ most commonly used to determine the perfusion to an organ: lung, 
heart, or brain. 
• 99mTc-MAA particles generally are in the range of 10–50 μm in 
diameter. 
Tc-99m macroaggregated albumin (MAA) for perfusion lung imaging 
(A) or a similar procedure for evaluation of liver blood flow (B)
Capillary blockage
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Physicochemical adsorption
• 99mTc-phosphonates accumulate in hydroxyapatite crystal
(containing Ca2+ and phosphate ions) matrix or in the
amorphous (noncrystalline) calcium phosphate
Tc-99m MDP bone scan
shows increased uptake in reactive
bone around metastatic tumors
• Sm-153 lexidronam (EDTMP) for 
treatment of painful bone 
metastases. 
Exchange of ionic chemical analogs, especially in a crystalline 
matrix.
✓exhange of Sr2+ / Ca2+ and F- / OH- in hydroxyapatite. 
• Bone imaging and bone metastases palliation beta–emmiter
89SrCl2 beta-emitter used to treat painful bone metastases, 
• Na18F, a PET agent used for bone scans 
Ion exchange
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Passive diffusion
• Random movement of molecules with the net effect 
toward achieving uniform concentration.
✓ passage across a membrane
✓ lipid solubility is an important property 
✓ pH/ionization - depending on the pH of the immediate 
environment 
✓ molecular size - small pores, or holes, that allow 
certain small molecules to pass through. Generally 
limited to molecules having a molecular weight of less 
than 80 daltons.
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Passive diffusion
Fick’s law of diffusion
✓ the rate of diffusion is a function of the concentration gradient
✓does not require the input of other external  energy
✓no transporters, carriers, or other receptors are involved so 
passive diffusion is non-selective
✓not competitively inhibited by similar molecules
✓not subject to saturation
e.g. Gases used for ventilation studies, such as 133Xe, 127Xe, and
81mKr, are inert lipophlic gases. After their administration through
inhalation, these gases are distributed within the lung air spaces by
diffusion.
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Passive diffusion
Influence of pH/ionization
The extent of ionization of a weak electrolyte depends on 
▪pKa of the drug
▪pH of the medium
Henderson - Hasselbalch equation
weak acids       weak bases
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Tc-99m DTPA brain imaging. Tc-99m DTPA cannot normally penetrate BBB
Disruption of the BBB (tumor, stroke, infection) causes Tc-99m DTPA to diffuse across
the disrupted BBB and accumulate in that affected area of the brain
Dynamic imaging after IV injection of Tc-
99m DTPA revealing stroke (A)
Delayed imaging at 3 hours after
Injection (B) shows increased 
accumulation of Tc-99m DTPA as a result of 
diffusion across a disrupted BBB.
Normal uptake of Tc-99m 
HMPAO in the
brain of a living person (A). 
• Delivery via passive diffusion 
+ retention – conversion 
to hydrophilic species
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• Delivery via passive diffusion + 
retention – enzymatic metabolism
SPECT imaging following ictus -injection of Tc-
99m bicisate (ECD) shows increased uptake in 
the seizure focus.
• Delivery via passive diffusion + retention by
electrostatic binding in mitochondria
Lipophilic, cationic 99mTc radiopharmaceuticals
(sestamibi, tetrofosmin, and furifosmin) have
been developed for imaging myocardial perfusion
http://clinicalgate.com/nuclear-medicine-imaging-of-myocardial-perfusion/
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Facilitated diffusion
✓ carrier-mediated, selective 
✓ can be competitively inhibited
✓ limited number of carriers - possible saturation 
✓ concentration gradient needed
✓ does not use external energy
e.g. cellular uptake of 18FDG reflects glucose 
metabolism
Following injection of 18FDG in a normal 
patient, there is high brain uptake, variable 
uptake in heart and moderate uptake in 
liver, GI tract, and marrow. 
18FDG is not reabsorbed by the distal
tubules so it remains in the urine.
Blood             Cell
GLUT
Glucose
18FDG
Glu-6-P
18FDG -6-P
Mitochondria 
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Active transport
✓carrier-mediated  
✓requires energy (ATP)
✓selective, can be competitively inhibited 
✓possible to achieve saturation
e.g. Iodide ions are transported into thyroid 
cells via the Na+/I- symporter.
I-123 and I-131 for thyroid function 
evaluation.
Tc-99m pertechnetate (TcO4-) is of similar 
ionic radius and a negative charge so it is 
also transported like iodide.
e.g. Na+/K+ pump, especially of importance 
in the heart muscle.
201TlCl myocardial perfusion scans.
82RbCl is used for PET myocardial perfusion 
scans. 
Absent thyroid uptake of Tc-99m 
pertechnetate in a patient who was 
administered iodinated x-ray contrast media 
a few days before.
Reduced uptake of Tl-201 in an area
of heart muscle due to stress-induced
ischemia in a patient with coronary artery 
disease (A) Normalization of uptake (B)
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Transport of monoamine neurotransmitters into 
neurons via norepinephrine transporter 
I-123 metaiodobenzylguanidine (MIBG) fits in this 
transporter. 
Overexpression occurs in certain neoplasms such as 
neuroblastoma and pheochromocytoma
I-123 MIBG demonstrates increased uptake in a 
pheochromocytoma in the right adrenal gland. Normal 
uptake is also seen in salivary glands, liver, heart, and 
bowel.
Active transport in the tubular cells of the renal 
cortex. 
Tc-99m succimer (DMSA) is taken up and retained
Tc-99m DMSA renal scans shows normal uptake throughout the 
renal cortex. Areas of decreased uptake in both the upper and 
lower poles of the right kidney are scar formation subsequent to 
recurrent kidney infections.
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Secretion
Special case of active transport out of glands and other tissues. 
➢ Gastric secretion, kidney tubular secretion, bile secretion 
(1) Diagnosis of present Meckel’s Diverticulum (a patch of ectopic stomach 
tissue) using Tc-99m pertechnetate (TcO4-) , ion of similar size and like charge to 
chloride (Cl-) 
(2) Tc-99m mertiatide (MAG3) for renal scan provides better contrast compared 
to radiopharmaceuticals eliminated by glomerular filtration 
(3) Liver scan with Tc-99m IDA (imino diacetic acid) agents (disofenin, 
mebrofenin) that are excreted using the same organic ion transport system as is 
used by bilirubin
1 2
3
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Cellular Migration and Sequestration
• 111In-oxine- or 99mTc-
HMPAO-labeled 
autologous mixed 
leukocytes 
(neutrophilic PMNs) 
are routinely used to 
image various 
inflammatory 
diseases and 
infectious processes.
• 111In-platelet 
localization at the 
site of active 
thrombus formation 
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Ventral (A) and dorsal (B) view of physiological distribution 
of 99mTc-HMPAO-labeled  lleukocytes one hour post injection
Filtration (pore/convective transport)
✓ Diffusion involving transit of molecules 
through pores/channels
✓ hydrostatic or osmotic pressure gradient. 
✓ molecular size vs. pore size.  (MW  < 5000 in 
glomerular filtration)
✓ requires some sort of force or pressure 
gradient
✓ no transporters, carriers, or other receptors 
are involved: non-selective, not 
competitively inhibited by similar molecules, 
not a subject to saturation
• radiopharmaceutical used for glomerular
function renal imaging is Tc-99m DTPA 
Pre-treatment with captopril, decreased 
glomerular filtration of Tc-99m DTPA is 
seen in the left kidney. As an ACE 
inhibitor,
captopril blocked the compensatory
mechanism activated by left renal artery 
stenosis, resulting in decreased 
glomerular pressure in the left kidney
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Phagocytosis (vesicular transport)
Cells engulf a particle and internalize it. 
Reticuloendothelial system (RES) cells (e.g. Kupffer cells in the liver)
• Tc-99m sulfur colloid, the traditional radiopharmaceutical used for liver scans 
is localized by this mechanism. Focal areas lacking Kupffer cells, such a tumor, 
cyst, abscess, or hemangioma, will be demonstrated as areas of lack of 
uptake (1)
In hepatitis or cirrhosis, there is typical ‘colloid shift’ – i.e., a shift in normal 
uptake away from the liver with increased uptake in the spleen and bone 
marrow (2)
1
2
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Localization of radiolabeled metabolic 
precursors and substrates
❖Metabolic Trapping of FDG
❖Radiolabeled Amino Acids
L-[methyl-11C] methionine: radiolabeled amino acid
uptake within tumors may reflect the increased protein
synthesis rate of proliferating tumor cells or simply an
increased rate of amino acid transport across the
tumor cell membrane
L-[1-11C]tyrosine, L-[2-18F]fluorotyrosine, L-4-[18F]fluoro-
m-tyrosine, and L-[3-18F]-a-methyltyrosine (FMT).
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Tissue hypoxia imaging
• 18F-fluoromisonidazole (FMISO) the most extensively 
studied hypoxia-selective radiopharmaceutical
2-nitro in misonidazole (MISO) is transported into the cell by diffusion.
In the cytoplasm, the nitro group (NO2) undergoes enzymatic
reduction to the free radical anion. In hypoxic tissue, the free
radical is further reduced to a reactive species, hydroxylamine, and
then to an amine and attached irreversibly to cellular
macromolecules and are retained within the cell.
• 64Cu-ATSM (Cu-diacetylbis-(N4-
methylthiosemicarbazone) is selectively trapped in 
hypoxic tissue but rapidly washed out of normoxic cells 
and is used for PET imaging 
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Cell Proliferation
• the growth rate of tumors correlates with their level of 
differentiation; 
• most malignant tumors grow more rapidly than benign 
tumors increased mitotic activity in tumor tissue 
increased requirement of substrates (nucleotides) for DNA 
synthesis
• 11C-Thymidine has been used for many years as a PET tracer 
to image tumors of the head and neck
• 125I-5-iodo-2’-deoxyuridine (IudR), an analog of thymidine, 
is phosphorylated and incorporated in DNA
• 18F-Fluoro-3’-deoxy-3’-l-fluorothymidine (FLT)- proliferation 
tracer (it is phosphorylated by TK, and TK activity is very 
high throughout the cell cycle in malignant tumors)
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Specific Receptor Binding
Somatostatin Receptors
Human SST receptors (SSTR) have 
been identified on many cells of 
neuroendocrine origin as well as 
on lymphocytes 
• most  neuroendocrine tumors, 
small cell lung cancers, and 
medullary thyroid carcinomas 
express SSTRs in high density
Imaging and therapy of SSTR-positive 
tumors
111In-DTPA-d-Phe1-pentetreotide 
(Octreoscan), 90Y-DOTA-Tyr3-
octreotide (DOTATOC)
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Specific Receptor Binding
Vasoactive intestinal peptide (VIP) Receptors
• Increased VIP receptor expression has been seen 
on adenocarcinomas, breast cancers, melanomas, 
neuroblastomas, and pancreatic carcinomas
• 123I-VIP shows specific uptake in primary tumors 
as well as in liver, lung, and lymph node 
metastases of pancreatic adenocarcinoma, colon 
adenocarcinoma, or gastrointestinal  
neuroendocrine tumors
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Specific Receptor Binding
Steroid Hormone Receptors
Majority of breast cancers are hormone dependent, as
indicated by increased expression of intracellular estrogen
or progesterone receptors
• 16α [ -[18F]fluoro-17 β -estradiol (FES)
• 21-[18F]fluoro-16α-ethyl-19-norprogesterone (FENP)
• 123I-labeled cis-11 β - methoxy-17α-iodovinylestradiol (Z-
[123I]MIVE)
transported into the cell by passive diffusion and bind to 
steroid receptors within the nucleus
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Specific Receptor Binding
LDL Receptors
Low-density lipoprotein (LDL) carries cholesterol to the adrenal glands as a 
substrate for synthesis of adrenal steroid hormones (cortisol and 
aldosterone)
• 131I-6 β -iodomethyl-19-norcholesterol (NP-59) is the agent of choice for 
imaging patients with adrenal cortical diseases.
• Normal adrenal glands show bilateral symmetrical uptake of NP-59.
Adrenal adenoma is identified as intense unilateral uptake while adrenal 
carcinoma shows no uptake of NP-59.
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Whole body scans were obtained 3 days (A), 5 days (B), 7 days (C) after injection of I-131 
NP59 1 mCi. Adrenal scan [59-[131I]iodocholesterol scanning (NP59 scan)] showed 
nodular activity in the region of left adrenal gland. Kim et al., J Korean Soc Endocrinol. 2006 Feb;21(1):58-62
Specific Receptor Binding
Radiolabeled Antibodies
radioiodinated, 99mTc-labeled, 111In-
and 90Y-labeled
I-131 tositumomab (Bexxar) and In-
111/Y-90 ibritumomab tiuxetan
(Zevalin), are monoclonal murine IgG
antibodies directed to CD20 
receptors on B-cells and non-
Hodgkin’s lymphoma tumor cells 
(treatment of NHL)
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Metabolism of drugs
Drug metabolism or biotransformation reactions are classified as:
Phase I functionalization reactions 
Introduce or expose (unmask) a functional group (-OH, -NH2, -SH, -
COOH) of the active substance 
➢ loss of pharmacological activity  or 
➢ formation of chemically reactive and more toxic, carcinogenic, or 
immunogenic metabolites
Phase II biosynthetic (conjugation) reactions 
Formation of a covalent linkage between a functional group on the 
active substance or phase I metabolite with endogenously derived 
glucuronic acid, sulfate, glutathione, amino acids, or acetate
➢ Highly polar conjugates 
➢ Generally are inactive and are excreted rapidly in the urine and feces 
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Metabolism of drugs
➢ The enzyme systems involved in Phase I reactions are located 
primarily in the endoplasmic reticulum.
These biotransforming reactions are carried out by:
Cytochrome P450 isoforms (CYPs) (mainly) and 
Flavin-containing monooxygenase (FMO)
Esterases
Amidases, etc.
These reactions are catabolic (e.g. oxidation, reduction or hydrolysis).
➢ The phase II conjugation enzyme systems are mainly cytosolic
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Cytochrome P450 (CYP)
• Cytochrome P450s (CYPs) are a superfamily of haem-
thiolate containing enzymes which play a major role in
the metabolism of many drugs and other xenobiotics.
A number of carcinogens are also metabolised by CYPs and it
is often these metabolites which are the ultimate carcinogenic
species.
• CYPs catalyse the oxidation of bound substrates
through the redox action of the hem moiety and the
activation of molecular oxygen and are able to carry
out a variety of hydroxylations, dealkylations and
hetero atom oxidations.
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• Substrate specificity is very low for the CYP enzyme
complex: high lipid solubility is the only common
property that renders CYP substrates a wide variety of
structurally unrelated drugs, ranging from a Mw of
28Da (ethylene) to 1203 Da (cyclosporine).
• Larger molecules (proteins) are not CYP substrates and
little is known regarding their catabolism.
It is believed that therapeutic proteins are metabolized by the same
catabolic pathways as endogenous proteins, and can be broken
down into amino acid fragments. Generally, the metabolic products
of proteins are not considered a safety risk and classical
biotransformation studies as performed for small molecules are not
needed.
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Cytochrome P450 (CYP)
CYP-mediated metabolism of 
radiopharmaceuticals
[18F]CPFPX
Implications of CYP-mediated metabolism during bolus/infusion PET 
studies in the pharmacokinetics of the radiotracer [18F]CPFPX, a 
novel PET ligand used for in vivo quantification of cerebral A1 
adenosine receptors in glioma.
In humans, this radioligand is metabolized to one major metabolite by 
CYP1A2 and at least 6 less abundant Phase I metabolites.
CYP1A2 –mediated preferential oxidation of [18F]CPFPX 46
[18F]CPFPX
• Its metabolism is expected to have a strict dependence 
on disease related or xenobiotic induced changes of 
CYP1A2 activity.
In patients with 
➢ liver disease (cirrhosis, hepatitis, etc.) or 
➢ exposure to CYP1A2 inducers (tobacco smoke, 
carbamazepine, omeprazole, etc.) 
➢ ihibitors (ciprofloxacin, phenacetine, etc.) 
it will result in an increase or decrease, respectively, in 
the metabolism of [18F]CPFPX and thus alter its plasma 
clearance and quantization of cerebral A1 adenosine 
receptors
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Metabolism of Radiometal-Labeled Proteins 
and Peptides
In the process of designing new radiometal-labeled mAbs and peptides 
for diagnostic imaging and targeted radiotherapy of cancer, the 
issue of metabolism of the radiopharmaceutical is often 
overlooked. 
When evaluating a nuclear medicine image of a radiolabeled mAb or 
peptide (taken by either gamma scintigraphy or PET), a question 
arises as what compound is actually being observed in the image? 
We can be certain of the purity of the radiopharmaceutical that was 
injected into the patient, but most of the time we are not certain 
• how rapidly the compound is metabolized
• the exact chemical form of the radiolabeled metabolite that is 
present at the various imaging times post-injection. 
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The fate of the radionuclide, i.e., whether it remains bound to the mAb
or peptide or whether it is metabolized, is of great significance, 
since this is what will ultimately determine the absorbed dose of 
the radiopharmaceutical to the tumor and normal tissues.
Understanding how radiometal-labeled proteins and peptides are 
metabolized requires taking several factors into consideration.
➢ the enzymatic breakdown of a protein or peptide into smaller 
peptide fragments that may or may not be attached to the 
radiometal chelate
➢ the enzymatic breakdown of the protein or peptide followed by 
acetylation or addition of another functional group
➢ dissociation of the radiometal from the chelator
Metabolism of Radiometal-Labeled Proteins 
and Peptides
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The metabolism of radiometal-labeled mAbsis highly dependent on 
the radiometal. 
e.g. The metabolism of 111In-and 90Y-labeled chelator-mAb/peptide 
conjugates has been shown to be significantly different than that of 
similar 64/67Cu-labeled protein and peptide conjugates. 
One study* with animal models focused on the metabolism of the 
anti-colorectal carcinoma mAb 111In-DTPA-1A3 and 111In-DTPA-1A3-
F(ab)2 in the liver and kidneys of rats. In the liver and kidneys low 
MW metabolites were present, most likely 111In-DTPA-Lys, but to a 
much greater extent in the kidneys than in the liver. Little or no 
evidence was observed for the dissociation of 111In from DTPA in 
these tissues.
Metabolism of Radiometal-Labeled Proteins 
and Peptides
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*Rogers BE, FrananoFN, Duncan JR, Edwards WB, Anderson CJ, ConnettJM, Welch MJ. Identification of 
metabolites of In-111-DTPA-monoclonal antibodies and antibody fragments in vivo. Cancer Res 
1995;55: 5714s.
The results of one study of DeNardo et al.* showed 
a significant amount of lower MW metabolites (non-identified) 
of 111In-and 90Y-labeled 2IT-BAD-Lym-1 
(2IT-BAD is 2-iminothiolane-2-[p-(bromo-acetamido)benzyl]-
1,4,7,10-tetraazacyclodo-decane-N,N9,N0,N-tetracetic acid) 
in the blood in non-Hodgkin’s lymphoma patients and 
normal volunteers (36% at 3 d post-injection); 
they also determined that there was no dissociation of these 
radiometals from the BAD chelator. 
Metabolism of Radiometal-Labeled Proteins 
and Peptides
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*DeNardo GL, DeNardo SJ, Kukis DL, O’Donnell RT, Mirick GR, Meares CF. Metabolite 
production in patients with lymphoma after radiometal-labeled antibody 
administration. J Nucl Med 2001;42:1324.
Routes of drug elimination
➢ Urine (kidney)
➢ Secretion into the GI tract (feces)
➢ Liver
➢ Lung
➢ Other sites such as skin, milk, tears, saliva.. 
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❖ Glomerular filtration 
• Non-selective, unbound substances with molecular
weight < 40,000 Da are eliminated by glomerular
filtration.
• Substances tightly bound to plasma proteins are not
filtered by the glomeruli
❖ Active tubular secretion
• many organic acids and some organic bases are 
actively secreted by renal tubules
❖ Passive and active tubular reabsorption lipid-
soluble drugs tend to be reabsorbed by the renal 
tubules and are not excreted
Mechanisms of renal excretion
Excretion and clearance of 
radiopharmaceuticals
Main pathways for excretion of RP:
Urine
Feces
Lungs (gases)
e.g. Radiolabeled peptides due to small Mw are 
excreted rapidly in urine. 
- Effective clearance of radionuclide
- Effective levels on receptor (tumor) site???
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Excretion and clearance of 
radiopharmaceuticals
The general formula for calculating clearance in first-order kinetics is:
CL = Vd x ke
Vd = volumen of distribution
Ke= excretion constant
For RP, excretion is calculated easily by renal clearance of blood:
CL = U x V x 1/B
U = urinary concentration of the radiopharmaceutical
V = volume of urine per time
B = blood concentration of the radiopharmaceutical
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